1428881-55-3

Basic information

• Product Name: 3-(5-fluoro-2-methoxyphenyl)-7-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benzo[d]isoxazole
• Synonyms: 3-(5-fluoro-2-methoxyphenyl)-7-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benzo[d]isoxazole
• CAS NO: 1428881-55-3
• Molecular Weight: 369.2
• Mol File: 1428881-55-3.mol

Chemical Properties

• CAS DataBase Reference: 3-(5-fluoro-2-methoxyphenyl)-7-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benzo[d]isoxazole(CAS DataBase Reference)
• NIST Chemistry Reference: 3-(5-fluoro-2-methoxyphenyl)-7-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benzo[d]isoxazole(1428881-55-3)
• EPA Substance Registry System: 3-(5-fluoro-2-methoxyphenyl)-7-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benzo[d]isoxazole(1428881-55-3)

Safety Data

• Hazardous Substances Data: 1428881-55-3(Hazardous Substances Data)

Upstream product

• 149947-15-9 3-bromo-2-fluorobenzaldehyde 
• 1428881-54-2 7-bromo-3-(5-fluoro-2-methoxyphenyl)benzo[d]isoxazole 
• 25015-63-8 4,4,5,5-tetramethyl-[1,3,2]-dioxaboralane 
• 1428881-53-1 (Z)-(3-bromo-2-fluorophenyl)(5-fluoro-2-methoxyphenyl)methanone oxime 
• 1428881-52-0 (3-bromo-2-fluorophenyl)(5-fluoro-2-methoxyphenyl)methanone 
• 188132-02-7 (5-fluoro-2-methoxyphenyl)magnesium bromide 
• 1428881-51-9 (3-bromo-2-fluorophenyl)(5-fluoro-2-methoxyphenyl)methanol 

Downstream Products

• 1428880-30-1 5-(3-(5-fluoro-2-methoxyphenyl)benzo[d]isoxazol-7-yl)pyrimidin-4-amine 
• 1428880-25-4 3-(5-fluoro-2-methoxyphenyl)-7-(4-methylpyrimidin-5-yl)benzo[d]isoxazole 
• 1428880-27-6 7-(4-cyclopropylpyrimidin-5-yl)-3-(5-fluoro-2-methoxyphenyl)benzo[d]isoxazole 
• 1428880-28-7 3-(5-fluoro-2-methoxyphenyl)-7-(4-(2,2,2-trifluoroethoxy)pyrimidin-5-yl)benzo[d]isoxazole 
• 1428880-24-3 3-(5-fluoro-2-methoxyphenyl)-7-(4-morpholinopyrimidin-5-yl)benzo[d]isoxazole 

Relevant articles and documents

SUBSTITUTED BICYCLIC HETEROARYL COMPOUNDS

Disclosed are azaindazole compounds of Formula (I): or a pharmaceutically acceptable salt thereof, wherein: X is O and Y is N; or X is S and Y is CH; Z is CR2 or N; Q is a heteroaryl; and R1 is defined herein. Also disclosed are methods of using such compounds in the treatment of at least one CYP17 associated condition, such as, for example, cancer, and pharmaceutical compositions comprising such compounds.